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Abstract
ERK signaling regulates focal adhesion disassembly during cell movement, and increased ERK
signaling frequently contributes to enhanced motility of human tumor cells. We previously found
that the ERK scaffold MEK Partner 1 (MP1) is required for focal adhesion disassembly in fibroblasts.
Here we test the hypothesis that MP1-dependent ERK signaling regulates motility of DU145
prostate cancer cells. We find that MP1 is required for motility on fibronectin, but not for motility
stimulated by serum or EGF. Surprisingly, MP1 appears not to function through its known binding
partners MEK1 or PAK1, suggesting the existence of a novel pathway by which MP1 can regulate
motility on fibronectin. MP1 may function by regulating the stability or expression of paxillin, a key
regulator of motility.
Introduction
Prostate cancer is the most commonly diagnosed cancer
in men. While in situ disease usually responds well to
treatment, progression to an androgen-hypersensitive,
metastatic state is often fatal [1]. Aberrant signaling
through the ERK pathway correlates with progression in
some models [2], although oncogenic mutations in Ras or
Raf occur infrequently in prostate cancer [3,4]. Rather,
prostate cancer commonly displays misregulation of cell-
matrix adhesion signaling, including alterations in
integrin expression and upregulation of Focal Adhesion
Kinase (FAK) and p21-Activated Kinase (PAK) [5,6]. We
have previously shown that PAK1 can activate MEK1 inde-
pendently of Raf in model systems [7] suggesting that this
alternative pathway to ERK activation may function in
tumor cells lacking oncogenic mutations in Ras and Raf.
Indeed, active PAK1 has been shown to stimulate ERK-
dependent proliferation of breast cancer cells [8], and is
constitutively active in DU145 prostate cancer cells [9].
MEK Partner 1 (MP1) is a putative scaffolding protein that
binds MEK1 and ERK [10]. MP1 also binds to the late
endosomal protein p14 [11], and the p14-MP1-MEK1
complex regulates trafficking and degradation of the EGFR
[12]. Thus MP1/p14 provides a means of colocalizing the
endocytosed EGFR and its downstream effectors during
proliferation stimulated by EGF. MP1 and p14 also play
important roles in cell morphogenesis and migration.
MP1 and/or p14 are required for efficient activation of
MEK and ERK, and control focal adhesion and actin
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dynamics during adhesion to fibronectin [13]. Since ERK
is known to regulate focal adhesion disassembly [14,15],
these observations implicate MP1-scaffolded ERK in focal
adhesion dynamics. However, MP1 also binds active
PAK1 [13], itself a regulator of adhesion disassembly
[13,16,17], consistent with alternative mechanisms for its
involvement in the regulation of cytoskeletal and adhe-
sion dynamics [13]. Elevated PAK activity is associated
with altered growth and migratory properties in a number
of tumor types, including prostate cancer [18]. We there-
fore investigated whether MP1 influences ERK and/or PAK
signaling during migration of DU145 prostate cancer
cells.
Materials and methods
Reagents
EGF (Invitrogen) and UO126 were from Calbiochem.
Gridded coverslips were from Bellco; glass-bottomed 35
mm microwell dishes were from MatTek Cultureware.
Both were coated with fibronectin as described [19].
Cell Culture
DU145 were maintained in RPMI-1640 containing 10%
fetal bovine serum (FBS, Invitrogen).
siRNA Assays
Cells (4.5 × 105 cells/100 mm dish plated two days prior
to transfection) were transfected with 100 nM control
siRNA (AGAGAGUAGUAGAGACAAUCGUCUG), MP1
Stealth siRNA (CAACACAGGACUAAUUGUCAGCCUA)
or p14 Stealth siRNA (UUAAGAUGCCGCCACUUGGGU-
GAGG) (Invitrogen) using Lipofectamine 2000 (Invitro-
gen) according to manufacturer's instructions.
Experiments were performed 72 hours post-transfection.
Immunoblotting
Cells were typically lysed in RIPA buffer (50 mM Tris, 150
mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 0.1%
SDS, 5 mM EDTA, 50 mM NaF) supplemented with 1 μg/
mL Leupeptin, 3 mM Benzamidine, 10 nM MicrocystinLR,
100 μM orthovanadate, 5 mM NaPPi, and 1 mM PMSF.
Equal amounts of lysate protein were used for immunob-
lots. Proteins were detected using the following antibod-
ies: MEK1 phospho-S298 [19]; MP1 [13]; MEK1 phospho-
S218/S222 (Sigma); phosphoERK1/2 (clone12D4;
Upstate) ERK1/2 phospho-T202/Y204 (Cell Signaling);
paxillin (Biosource); PAK1 N-20 (Santa Cruz); pS141
PAK1-3 (Invitrogen). p14 antibody #5933 was raised
against the peptide sequence Ac-
CLKAKAQALVQYLEEPLTQVAAS-OH and affinity puri-
fied using standard techniques. Blots were imaged on an
LAS-1000 Plus Intelligent Dark Box (Fujifilm) using
Image Reader software (Fujifilm); the same software was
used for quantification of immunoblot results.
Adhesion/EGF stimulation assay
Cells were plated on fibronectin essentially as described
[13]. For EGF stimulation, cells were washed in serum-free
(SF) medium then fed SF medium for 2 hours prior to
stimulation.
Migration assays
Cells were trypsinized and collected in SF medium con-
taining 1 mg/mL soybean trypsin inhibitor (Sigma), pel-
leted, suspended in SF medium and incubated at 37°C for
two hours. 2 × 106 cells were allowed to form confluent
monolayers on fibronectin-coated grid-etched coverslips
for 5-7 hours at 37°C. Cells were treated with 1 μg/mL
Mitomycin C (Sigma) and either 25 μM UO126 or DMSO
vehicle for an additional 3 hours. The medium was aspi-
rated and the coverslip was scratched 4 times with a 200
μL tip to form a # wound pattern. Loose cells were
removed with SF medium; cells were fed fresh SF medium
containing 1 μg/mL of Mitomycin C and either 25 μM
UO126 or the equivalent volume of DMSO, with or with-
out 1% FBS or 10 ng/mL EGF as indicated. Wounds were
photographed in 6 different locations at zero-hour time
point, and then incubated at 37°C for 5 hours (trans-
fected cells) or 10 hours (untransfected cells) at which
time the same locations were photographed. All photo-
graphs were taken with an Olympus IX81 microscope
equipped with Slidebook software (Intelligent Imaging
Innovations) and the area covered by migrating cells was
calculated using ImageJ software (NIH). Parallel cultures
were processed for immunoblotting.
Immunofluorescence
Immunofluorescence was carried out essentially as
described [13] using a Leica DMRA2 microscope
equipped with Slidebook software. The number and size
of vinculin-positive focal adhesions at the wound edge
was calculated using Slidebook software.
Kymography
2 × 106 cells were plated on 35 mm FN-coated glass-bot-
tomed Petri dishes in SF medium with 1 μg/mL Mitomy-
cin C and allowed to adhere for 5-7 hours. Confluent
monolayers were wounded and imaged starting 10-20
min post wounding and again after 2 hours of migration.
All cells were imaged for 5 minutes at 1 frame per second
on an Olympus IX81 microscope equipped with Slide-
book software. Kymographs were generated using ImageJ
software.
Statistical Analysis
Wound-healing assays were repeated in triplicate and sta-
tistical analysis was performed on the pooled results. A
general linear model was constructed and linear contrast
was used to perform pairwise comparisons of the means
for the combined data set. Tukey's Honestly SignificantCell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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test was used for post-hoc pairwise comparisons of migra-
tion under experimental conditions to that of migration
under SF conditions and to each other. ANOVA on pooled
data indicated significant differences within the data set.
Results
ERK activity is required for growth factor-, but not 
fibronectin-stimulated, DU145 migration
We developed a quantitative wound-healing assay that
makes use of gridded coverslips to allow for accurate
measurement of migration into a wounded monolayer
over time (Fig. 1B; Materials and Methods). To distinguish
between wound closure due to cell movement and prolif-
eration, mitosis in these assays was inhibited by the inclu-
sion of 1 μg/mL mitomycin C; this concentration was
determined as the minimal dose needed to prevent
DU145 proliferation without inducing cell death under
serum-free conditions (data not shown). Additionally, to
distinguish between cell spreading and motility, cells were
tracked in real time over the course of the assay (data not
shown), and movies were analyzed for directionality and
distance migrated. From these assays we were able to
determine that DU145 are migrating into the wound in
the monolayer over the timecourse of the assay. DU145
cells migrated 65 ± 3.5 μm2 on fibronectin in serum-free
conditions, and pre-treatment with 25 μM UO126 for 3 hr
had no effect (Fig. 1A). Migration on fibronectin was
increased to 115 ± 4.9 and 100 ± 5.3 μm2 in the presence
of 1% serum or 10 ng/mL EGF, respectively, and these
increases were significantly inhibited by UO126 (Fig. 1A).
Thus, MEK signaling is required for growth-factor-
induced, but not for fibronectin-stimulated, migration of
DU145 cells.
MP1/P14 is required for migration of DU145 cells on 
fibronectin
Since fibronectin-stimulated motility of DU145 cells is
insensitive to MEK inhibitor (Fig. 1A), we predicted that
ERK activation is not required for DU145 migration on FN, but is required for migration on FN induced by serum Figure 1
ERK activation is not required for DU145 migration on FN, but is required for migration on FN induced by 
serum. A) Results of DU145 wound healing on FN. Shown are averaged results from 4 experiments; error bars represent 
standard error of the mean (S.E.M.). Migration in response to fibronectin alone was not affected by UO126. Serum and EGF 
stimulated significant (p < 0.0001) increases in migration, that were significantly inhibited (p < 0.0001 for serum, p = 0.0004 for 
EGF) by UO126 treatment. B) Sample images from wound healing assay; for each condition, six grid squares were imaged at 0 
and 10 h post-wounding, and wound area (outlined in white) was measured using ImageJ software (NIH).Cell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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MP1 depletion would be similarly without effect on
fibronectin-stimulated DU145 migration. However, since
MEK activity is required for growth-factor stimulated
DU145 motility (Fig. 1A), and MP1 is required for EGF-
and serum-stimulated MEK/ERK activation in fibroblasts
[13,20], we predicted that MP1 depletion would inhibit
growth-factor stimulated motility of DU145 cells. Surpris-
ingly, we found that fibronectin-stimulated motility was
inhibited by ~50% following transfection with MP1
siRNA (Fig. 2A, white bars). In contrast, the component of
motility stimulated by 1% serum (above and beyond that
stimulated by fibronectin alone) was unaffected by trans-
fection of MP1 siRNA, but was substantially inhibited by
UO126 (Fig. 2A) as in naïve cultures (Fig. 1A). Consistent
with these observations, depletion of MP1/p14 did not
substantially inhibit levels of active ERK or active MEK in
cells on fibronectin, whether or not they were exposed to
growth factor (Fig. 2B), whereas UO126 essentially elimi-
nated ERK activity in both control and MP1 siRNA-trans-
fected cells (Fig. 2B). Note that knock-down of MP1 is
difficult to measure accurately due to the presence of
closely migrating proteins that cross react with our anti-
body. However, siRNAs targeting MP1 have been shown
to cause a simultaneous reduction in p14 expression, and
vice versa [13,21], most probably because the MP1-p14
heterodimer is more stable than the individual subunits.
Since our p14 antiserum blots more cleanly, we used p14
levels as a surrogate measure for MP1 knockdown. p14
levels were reduced on average by 82% (Fig 2B; data not
shown). Together, these data indicate that MP1/p14 but
not MEK signaling is required for fibronectin-stimulated
motility of DU145 cells, whereas MEK signaling but not
MP1/p14 is required for motility stimulated by serum
growth factors. Thus MP1/p14 and MEK play separable
roles in DU145 migration.
MP1 depletion decreases membrane activity and 
peripheral focal adhesions in migrating cells
We next asked whether membrane protrusion or focal
adhesions were altered in DU145 cells lacking MP1/p14.
Kymograph analysis allows visualization of the mem-
brane boundary over time; the y-value is determined by
the position of the membrane edge, and the x-axis repre-
sents time [21,22]. Cells in MP1 siRNA-transfected cul-
tures displayed much less protrusive and ruffling activity
at the wound edge relative to control siRNA-transfected
cells (Fig. 3A).
To examine focal adhesions in these assays, a monolayer
was wounded and fixed after cells had migrated for 5 hrs.
Control- and MP1 siRNA-transfected cells display adhe-
sions of similar total number and size distribution (Fig.
3B, C). However, MP1 siRNA-transfected cells have ~50%
fewer adhesions at the wound edge (Fig. 3B; defined as
adhesions occurring between the cell periphery and the
cortical actin ring, not shown; vinculin spots occurring at
sites of cell-cell contact were not counted as focal adhe-
sions). This suggests that early nucleation events required
for adhesion formation at the wound edge occur at a
lower frequency in cells depleted of MP1/p14, or that
turnover of this population of adhesions is more pro-
nounced in cells lacking MP1/p14.
Depletion of MP1/p14 modestly inhibits PAK activity
Membrane protrusion and ruffling are governed in part by
localized Rac/PI3-Kinase signaling, while membrane
extensions are stabilized by focal complexes that also
require PAK activity [16,17]. Focal adhesion maturation
and disassembly are complex processes governed by
GTPases (including Rac and Rho), kinases (including
PAK, FAK, and ERK) and molecular organizing compo-
nents including paxillin. Since fibronectin-stimulated
DU145 motility was insensitive to MEK inhibitor but sen-
sitive to knock-down of MP1/p14, we reasoned that MP1
functions through a MEK activity-independent pathway to
regulate membrane and adhesion dynamics. One candi-
date molecule is PAK1, to which MP1 binds [13]. Group I
PAK kinases phosphorylate a number of cellular targets,
including MEK1 [7,19,23], paxillin [24], and themselves
[25,26]. Depletion of MP1/p14 slightly delays autophos-
phorylation of PAK1-3 on S141 following adhesion to
fibronectin, with phosphorylation recovering around 1 hr
and persisting throughout the 5 hr time course. Maximal
phosphorylation of MEK1 on S298 is similarly delayed in
MP1 siRNA-transfected cells (Fig. 4A). While we cannot
exclude that these subtle differences in kinetics of phos-
phorylation in the population as a whole represent signif-
icant quantitative differences at the wound edge, our data
suggest that depletion of MP1/p14 has minor effects on
the overall activity of the PAKs phosphorylating these sub-
strates.
Paxillin is largely absent in DU145 cells depleted of MP1/
p14
To extend these observations, we asked whether PAK
phosphorylation of the cytoskeletal linker/adapter paxil-
lin was regulated by MP1/p14. Paxillin has been shown to
play essential roles in focal adhesion dynamics, mem-
brane protrusion and motility [14,27-29]. PAK phospho-
rylates paxillin on S273, and phosphorylation of this site
is required for stabilizing membrane protrusion [24]. Sur-
prisingly, the abundance of paxillin was substantially
reduced in cells depleted of MP1/p14 (~60% reduction,
Fig. 4B), suggesting that paxillin is poorly expressed or
unstable in cells lacking MP1/p14, or that it resides in a
compartment not extracted by our lysis buffer. To exclude
the latter possibility, we prepared extracts in SDS-PAGE
sample buffer which is expected to solubilize all cellular
proteins. The abundance of paxillin was similarly reduced
(by ~60%) in SDS-PAGE buffer extracts of DU145 cellsCell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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MP1 knockdown inhibits migration in DU145 acutely adherent on fibronectin Figure 2
MP1 knockdown inhibits migration in DU145 acutely adherent on fibronectin. A) DU145 cells were transfected 
with Control (non-targeting) or MP1 siRNA. MP1 depletion inhibits DU145 migration on FN in serum-free medium (SF) by 
~50% relative to control. Migration is induced by 1% fetal bovine serum (1%) in cells transfected with control or MP1 siRNA, 
and the induced component of migration is sensitive to MEK1 inhibition by UO126 (UO). Shown are mean data from three 
independent experiments; error bars represents S.E.M. B) Representative blot showing MP1 knockdown in DU145 cells 
treated in parallel with cells in wound-healing assay. Two exposures of MEK1 phospho-SS218/222 are shown to emphasize the 
low level of MEK1 activation in these assays, which nevertheless remains similar between Control and MP1 siRNA transfected 
cells. SF, Serum-Free medium; S, 1% fetal bovine Serum medium; S/U, 1% fetal bovine Serum medium + 25 μM UO126.Cell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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MP1 depletion decreases membrane activity and the number of focal adhesions at the wound edge Figure 3
MP1 depletion decreases membrane activity and the number of focal adhesions at the wound edge. A) DU145 
cells transfected with control or MP1 siRNA were wounded as described. Approximately 2 hours post-wounding, cells were 
imaged at 1 second intervals for 5 min for kymograph analysis. For each cell, 6-7 kymographs were generated (shown by num-
bered lines); 5-7 cells per condition were analyzed. Boxes around the number indicate the representative kymograph shown. 
B) Control and MP1 siRNA transfected cells plated on coverslips and imaged for a wound-healing assay were fixed and stained 
for vinculin to mark focal adhesions. Average number and size of FA occurring at the wound edge were quantified using ImageJ 
(chart). C) Size distribution of all focal adhesions in the cells imaged for B. MP1 depleted cells have fewer focal adhesions at the 
wound edge.Cell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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MP1 knockdown modestly delays PAK autophosphorylation in response to FN and decreases paxillin expression Figure 4
MP1 knockdown modestly delays PAK autophosphorylation in response to FN and decreases paxillin expres-
sion. A) DU145 cells transfected with control or MP1 siRNA were plated on FN for the times indicated. Whole cell lysates 
were analyzed by immunoblot for PAK phosphorylation of MEK1 (pS298 MEK1) and PAK1-3 autophosphroylation on S141. B) 
Cells transfected with control or MP1 siRNA were lysed in RIPA (RIPA) or SDS-PAGE (SDS) loading buffer (see Methods) and 
expression of focal adhesion proteins was assessed by immunoblot. C, Control siRNA; M, MP1 siRNA. Paxillin expression was 
quantified by densitometry and is expressed as percent of control for each lysis buffer. C) Cells transfected with control, MP1, 
or p14 siRNA were analyzed for vinculin, paxillin, MP1 and p14 expression.Cell Communication and Signaling 2009, 7:26 http://www.biosignaling.com/content/7/1/26
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transfected with MP1 siRNA, while expression of other
focal adhesion markers vinculin, talin and zyxin was unaf-
fected by knock-down of MP1/p14 (Fig. 4B). Reduction of
paxillin levels is unlikely to result from off-target effects of
the MP1 siRNA since similar results were obtained with an
independent p14 siRNA (Fig. 4C). These data indicate that
the MP1 and/or p14 are required to maintain normal pax-
illin protein levels.
Discussion
MP1/p14 regulated signaling events
MP1/p14 is essential for ERK activation during adhesion
of fibroblasts to fibronectin, and in this context, depletion
of MP1/p14 causes an apparent stabilization of focal
adhesions [13]. We therefore predicted that depletion of
MP1/p14 would cause inhibition of fibronectin-stimu-
lated ERK activation and stabilization of focal adhesions
in DU145 cells, and thus inhibit cell motility. To our sur-
prise, we found that migration of DU145 cells on
fibronectin does not require acute MEK activity but does
require MP1/p14. Conversely, migration stimulated by
growth factors requires acute MEK activity, but does not
require MP1/p14. Furthermore, MP1/p14 depletion does
not significantly inhibit ERK phosphorylation in response
to fibronectin or growth factor stimulation. These data
indicate that there are separable MEK activity- and MP1/
p14-dependent pathways leading to DU145 motility in
response to serum growth factors and fibronectin respec-
tively.
Because Group I PAKs have multiple roles in cell motility
[30] and PAK1 binds MP1 [13], we reasoned that MP1
might function through PAK to regulate fibronectin-stim-
ulated DU145 migration. However, depletion of MP1
caused only modest differences in PAK autophosphoryla-
tion or PAK phosphorylation of MEK1; phosphorylation
of the PAK-dependent substrate cofilin was also unaf-
fected by depletion of MP1 (data not shown). These data
suggest that PAK is not a major effector for MP1 in DU145
cell motility.
MP1/p14 is required for maintenance of paxillin levels
Surprisingly, we found that paxillin was largely absent
from DU145 cells depleted of MP1/P14 while expression
of other focal adhesion proteins was unaffected. Future
experiments will determine whether this loss of paxillin
results from decreased mRNA or protein synthesis, or
increased turnover of paxillin protein.
Depletion of MP1/p14 influences membrane dynamics and 
focal adhesion abundance
We have found that depletion of MP1/p14 results in a loss
of paxillin, decreases membrane protrusion, and reduces
the number of focal adhesions at the wound edge. Paxillin
serves as a signaling nexus at focal adhesions and in the
leading edge of migrating cells. In particular, the GIT1-
PIX-PAK complex is stabilized by PAK phosphorylation of
paxillin, leading to increased localized Rac activation,
membrane protrusion, and migration [24]. This complex
localizes to a population of dynamic focal complexes at
the leading edge [14,24], suggesting that it may be impor-
tant for stabilizing membrane protrusion. Alternatively,
paxillin may liberate p190A RhoGAP from p120 RasGAP
at the leading edge of motile cells [31]. Locally released
p190A RhoGAP is free to stimulate hydrolysis of GTP on
Rho allowing membrane protrusion. Interestingly, while
the loss of paxillin correlates with a failure of DU145 to
migrate on fibronectin, it does not preclude serum-stimu-
lated motility.
Our data are the first to indicate that MP1/P14 has impor-
tant functional roles outside the ERK pathway. These
observations suggest that MP1/p14- and paxillin-depend-
ent and -independent pathways for motility may be oper-
ational in DU145 cells in a context-specific manner.
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